The company is said to have increased the production to supply the US market and meet the clinical needs of health care professionals.
Propofol, marketed under the brand name, Diprivan, is a fast-onset sedative-hypnotic agent used for the induction and maintenance of anesthesia or sedation.
APP Pharmaceuticals president and CEO John Ducker said in order to maintain a consistent supply of this drug, the company has responded promptly in the face of drug shortages to meet market demand.